Novel β-lactamase inhibitors and the pursuit of MBL inhibitors to combat antibiotic-resistant bacteria: a review

Abstract

Bacterial resistance is spreading internationally and poses a serious threat to humans. β-lactam resistance has enhanced to an uncontrolled rate due to many reasons. The most significant form of resistance is destruction of the ß-lactam ring by a bacterial enzyme named ß-lactamase enzyme which is essential for antibacterial activity. There are currently six β-lactamases inhibitors that can be used clinically in conjugation with the antibiotic in order to protect them from enzymatic attacks. They bind the β-lactamase enzyme thus the β-lactam antibiotic catches the transpeptidase (PBP) which has the responsibility of peptidoglycan synthesis and disables it thus causing cell wall lysis. However, in order to tackle the fast escalating ß-lactam resistance, additional research is needed in order to create novel drugs with broad-spectrum. Herein we represent the recently published works of the β-lactamases inhibitors. Until nowadays there are no clinically approved MBL inhibitors, Efforts should be put to discover and evaluate novel MBLi to impede the spread of pathogenic-resistant bacteria and minimize their global health impact. The scientists realize this fact and emphasize their effort toward MBL inhibitors.